B7-2/GM-CSF cancer gene therapy

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameB7-2/GM-CSF cancer gene therapy

Drug Alias NameCIT

ClassificationCell and gene therapy > Gene therapy

Mechanisms of ActionGranulocyte-macrophage colony-stimulating factor receptor stimulantsT-cell-specific surface glycoprotein CD28 agonistsCytotoxic T-Lymphocyte-Associated Antigen 4 stimulants

TargetsGranulocyte-macrophage colony-stimulating factor receptorT-cell-specific surface glycoprotein CD28Cytotoxic T-Lymphocyte-Associated Antigen 4

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesRadient

China Registration ClassN/A

Develop Information

Active CompaniesRadient

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A